Now imagine a world where the best scientists that knew the 1D structure of the ribbon very well but could not tell you how a piece of ribbon will land until they threw it up in the air. All they could do when they discovered a piece of ribbon was to throw it, collect it, and then use very expensive machines to measure it carefully to determine the structure of this mess. And each of these measurements took 3-4 years of a scientist to do. And then only learn about this piece of ribbon. For the next one, they had to start over. This is what we do for proteins. The ribbon is the 1D structure and the mess on the floor is the 3D structure.
In nature, what is truly mind blowing is that proteins don’t try out the millions of different configurations before settling into the final one, they just ‘know’ which one is the right one and generations of scientists have been baffled by it. Given the complexity of different forces and constraints acting on different atoms in each amino acid in the chain: hydrogen bonds, van der Waals interactions, electrostatic interactions each step in the folding process changes the configuration such that the rest of the protein chain now operates in entirely different space. Ultimately, the 3D structure will be determined by what configuration of the amino acids is thermodynamically stable. This means that to solve the problem by brute force unless you know what happens first you can’t guess what will happen next. In many cases the protein folding takes place within seconds which makes the overall complexity of this problem overwhelming.
Is The Protein Folding Problem Really Solved?
Despite this being the biggest thing that has happened in protein folding, the protein folding problem is not yet solved. Compared to the problem of protein folding, CASP is a game. It is a very hard game but it is a reduced problem set which helps us train our tools and standardise performance. It is a necessary step but it is not sufficient. AlphaFold has aced CASP13 which is not a minor achievement and the start of something new and something big but it is not something where we can enter 1D data at one end and start getting 3D data on the other. We are a fair bit away from that. AlphaFold solves the ‘what’ of the problem in a limited way but not the ‘how’ of the problem yet but this is also probably the best chance for us to eventually solve the ‘how’.
What is the best thing about AlphaFold is also what limits its value in other ways. A black box approach has the problem of not being able to know if the ab initio structure of a new protein predicted by AlphaFold is the right one. Scientists will continue to confirm AlphaFold’s predictions in real work anyway.
And finally, while the results have been released the actual algorithm is not available for use by scientists at this moment. Given that DeepMind is not a publicly funded research institution, it may never be published.
How Will this Impact the Healthcare Industry?
Nothing will happen overnight and at least not directly in the classical drug discovery pathway. Even if we had a magical algorithm which would spit out 3D structure of every protein on demand, the major impact of this new invention will certainly not be on classical drug discovery. In the 90’s we thought if only we had high resolution structures of more proteins we would have more novel drugs. In my previous fund, we even invested in a company doing just that. We now realise that just having more protein structures may not lead to more drugs because we have thousands of high resolution structures already and most of them remain ‘undruggable’ (i.e. not accessible to being interfered with for medical purposes). And many of our challenges are downstream from knowing protein structure.
That said, the possibilities this opens are far more exciting than just classical drug discovery. We expect algorithmes like this will evolve to help us understand protein-protein interactions better. We are currently at a very early stage of understanding these interactions and this is an area we are very excited about. At Molten (previously Draper Esprit), we invested in Fluidic Analytics which developed a device for understanding protein interactions (I wrote about this before: Social Network, But For Proteins). They are applying it to understanding interactions between antibodies and their targets (including in COVID-19).
Another area where such an algorithm could help us make a big leap is to understand protein misfolding. Distorted, degraded and dysfunctional proteins cause many deadly diseases and play a role in ageing and inflammation.
The third area which is a bit longer term but could transform a whole industry is synthetic biology. By reverse engineering our knowledge of protein folding we could start synthesising proteins which analogues of which have never existed in nature but designed for a specific function. This has been tried but is currently it is too slow to be truly impactful. We have often imagined that many use cases for Evonetix (our investment in DNA synthesis in Cambridge) would include designing proteins on demand for a certain function rather than replicating what already exists in nature. As with any new technology the benefits are likely to be things we cannot even envisage today. But if you want to take a peek, try this TED Talk by David Baker (David’s Rosetta Consortium used to win most CASP competitions before AlphaFold showed up… much like Arsenal before Manchester City)
To understand what this discovery means we have to take a step back and reflect. Like many things, the achievements of AlphaFold will be overestimated in the short term (hyperventilating press coverage is already here!) but underestimated in the long run. We often look back on the 20th Century for its achievements in biology, but It is truly amazing to be living in this century of advancements in biology and watching some of the biggest problems being solved in front of our very eyes. At Molten (previously Draper Esprit), we’re excited to be doing our small part in helping turn these discoveries into the businesses of tomorrow, if you are building a business in healthtech, come and talk to us.
